Barriers to Accessing and Engaging in HIV Preventive Care and Pre-Exposure Prophylaxis Experienced by Transgender Women in Florida
Authors:
- Allysha C. Maragh-BassAMAllysha C. Maragh-Bass
- Sandra KiplagatSKSandra Kiplagat
- Sarah LavariSLSarah Lavari
- Francisco SastreFSFrancisco Sastre
- Jessy G. DevieuxJDJessy G. Devieux
- Daniel JimenezDJDaniel Jimenez
- Rachel D. ClarkeRCRachel D. Clarke
- Ines NoelINInes Noel
- Eric W. SchrimshawESEric W. Schrimshaw
- Jae SeveliusJSJae Sevelius
- Elena CyrusECElena Cyrus
Open Access
- 21 March 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (3) , 376
Abstract
Background: PrEP, a biomedical HIV prevention option, continues to be underutilized among transgender women who could benefit from sustained use, especially women of color and those who identify as Latina and/or reside in the southeastern US. Objective: We explored the barriers and facilitators experienced by transgender women who live in Florida regarding accessing, using, and/or staying on PrEP. Methods: In-depth interviews and focus groups were conducted in either Spanish or English with adult transgender women living in Florida (N = 22). The interviews were audio-recorded, transcribed, and coded in ATLAS.ti using thematic analyses. Results: The mean age of the participants was 42.2 years. Among the participants, 73% were Hispanic/Latina, 59% were foreign-born, and approximately one-third were living with HIV (but had past experience with PrEP). Transgender women cited the following barriers to accessing or considering PrEP: (1) costs and benefits of PrEP use; (2) under-representation in clinical trials resulting in unknown or misinformation regarding PrEP side effects; (3) chronic poverty; and (4) trauma and discrimination. Other stressors, such as behavioral healthcare needs, were identified. Conclusions: Our analysis revealed interlocking systems of oppression like transphobia, discrimination, and misgendering, which were common barriers experienced by our participants. These synergistically epidemic (i.e., syndemic) barriers contributed to their feelings of being systematically excluded in social spaces, research, public health planning and policies, laws, and social programs related to PrEP. These structural barriers are impediments to HIV preventive care but also act as a source of stress that contributes to mental health problems, financial vulnerability, substance abuse, and other deleterious health outcomes.Keywords
Funding Information
- National Institute on Drug Abuse (NIDA) (K99/R00 DA046311, L30AA027051)
- National Institutes of Health (K99/R00 DA046311, L30AA027051)
This publication has 23 references indexed in Scilit:
- Engagement in Care and Housing Instability Influence HIV Screening Among Transgender Individuals in South FloridaTransgender Health, 2022
- Disparities of HIV risk and PrEP use among transgender women of color in South FloridaJournal of the National Medical Association, 2019
- Strategies for engaging transgender populations in HIV prevention and careCurrent Opinion in HIV and AIDS, 2019
- PrEP indicators, social capital and social group memberships among gay, bisexual and other men who have sex with menCulture, Health & Sexuality, 2019
- Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York CityAIDS and Behavior, 2018
- Demographic Characteristics, Components of Sexuality and Gender, and Minority Stress and Their Associations to Excessive Alcohol, Cannabis, and Illicit (Noncannabis) Drug Use Among a Large Sample of Transgender People in the United StatesJournal of Prevention, 2017
- Transgender Women in Clinical Trials of Pre-Exposure ProphylaxisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
- HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trialThe Lancet HIV, 2015
- Inclusion of trans women in pre-exposure prophylaxis trials: a reviewAIDS Care, 2014
- Worldwide burden of HIV in transgender women: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2013